Lee Soo-Young, Ahn Chul-Soo, Yoon Young-In, Lee Sung-Gyu, Hwang Shin, Kim Ki-Hun, Moon Deok-Bog, Ha Tae-Yong, Song Gi-Won, Jung Dong-Hwan, Park Gil-Chun
Department of Surgery, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
Division of Hepatobiliary Surgery and Liver Transplantation, Department of Surgery, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
Ann Hepatobiliary Pancreat Surg. 2020 Nov 30;24(4):437-444. doi: 10.14701/ahbps.2020.24.4.437.
BACKGROUNDS/AIMS: Surgical resection for the treatment of multiple hepatocellular carcinomas (HCCs) is controversial. This study aimed to evaluate the clinical and oncological outcomes after liver resection in patients with multiple HCCs.
Clinicopathological and survival data of 187 patients who underwent curative resection for multiple HCCs between June 2004 and December 2016 at Asan Medical Center, Seoul, South Korea were retrospectively reviewed. The prognostic factors for recurrence and survival were identified using univariate and multivariate analyses.
Of the 187 patients, 153 (81.8%) had two nodules, 23 (12.3%) had three nodules, and 11 (5.9%) had more than three nodules. Multiple tumors were located in the ipsilateral lobe in 163 (87.2%) patients. Anatomical resection, non-anatomical resection, and both types of resections were performed in 81.3%, 8.0%, and 10.7% patients, respectively. Recurrence occurred in 133 (71.1%) patients, and the mean time to recurrence after surgery was 34.2 months. Independent risk factors for tumor recurrence in multivariate analyses were indocyanine green retention rate at 15 min ≥15%, preoperative alpha-fetoprotein level ≥400 ng/ml, and total tumor diameter ≥6 cm. The 1-, 3-, 5-, and 10-year disease-free survival rates were 94.1%, 81.7%, 69.7%, and 39.4%, respectively, and the 1-, 3-, 5-, and 10-year survival rates were 93.5%, 74.2%, 64.9%, and 38.8%, respectively.
Our experience shows that liver resection can be considered a first-line treatment option for selected patients with multiple HCCs who have well-preserved liver function.
背景/目的:手术切除治疗多发性肝细胞癌(HCC)存在争议。本研究旨在评估多发性HCC患者肝切除术后的临床和肿瘤学结局。
回顾性分析2004年6月至2016年12月在韩国首尔峨山医学中心接受根治性切除治疗多发性HCC的187例患者的临床病理和生存数据。采用单因素和多因素分析确定复发和生存的预后因素。
187例患者中,153例(81.8%)有两个结节,23例(12.3%)有三个结节,11例(5.9%)有三个以上结节。163例(87.2%)患者的多个肿瘤位于同侧叶。分别有81.3%、8.0%和10.7%的患者接受了解剖性切除、非解剖性切除和两种切除方式。133例(71.1%)患者出现复发,术后复发的平均时间为34.2个月。多因素分析中肿瘤复发的独立危险因素为15分钟吲哚菁绿滞留率≥15%、术前甲胎蛋白水平≥400 ng/ml和肿瘤总直径≥6 cm。1年、3年、5年和10年无病生存率分别为94.1%、81.7%、69.7%和39.4%,1年、3年、5年和10年生存率分别为93.5%、74.2%、64.9%和38.8%。
我们的经验表明,对于肝功能良好的部分多发性HCC患者,肝切除可被视为一线治疗选择。